How long does VK2735 take to work?
In the first week of VK2735, trial data: appetite drops early, mild-to-moderate nausea is the most common effect at the start. Around week 4, progressive weight loss across all doses in the Phase 2 VENTURE program. By week 8, loss kept building with no plateau seen by the 13-week trial endpoint. Response varies between people, this is the commonly reported pattern, not a guarantee.
Week by week
- Week 1: Trial data: appetite drops early, mild-to-moderate nausea is the most common effect at the start.
- Week 4: Progressive weight loss across all doses in the Phase 2 VENTURE program.
- Week 8: Loss kept building with no plateau seen by the 13-week trial endpoint.
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on VK2735
Last updated 2026-06-15.